江苏艾迪药业股份有限公司 董事会薪酬与考核委员会 关于 2025 年股票期权激励计划 首次授予激励对象名单的审核意见及公示情况说明 证券代码：688488 证券简称：艾迪药业 公告编号：2025-036 2、激励对象不存在《管理办法》规定的不得成为激励对象的情形： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日召开 第三届董事会第四次会议、第三届监事会第四次会议，审议通过了《关于公司＜ 2025 年股票期权激励计划（草案）＞及其摘要的议案》等相关议案。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）《上海证券 交易所科创板股票上市规则》《科创板上市公司自律监管指南第 4 号——股权激 励信息披露》的相关规定，对公司《2025 年股票期权激励计划（草案）》（以下 简称"《激励计划（草案）》"、"本激励计划"）中拟首次授予激励对象的姓名和职 务在公司内部进行了公示。公司董事会薪酬与考核委员会结合公示情况对本激励 计划拟首次授予激励对象 ...

江苏艾迪药业股份有限公司 2025 年第二次临时股东会会议资料 二○二五年七月 江苏艾迪药业股份有限公司 2025 年第二次临时股东会会议资料 江苏艾迪药业股份有限公司 2025 年第二次临时股东会会议资料目录 | 2025年第二次临时股东会会议须知 | 3 | | --- | --- | | 2025年第二次临时股东会会议议程 | 5 | | 2025年第二次临时股东会会议议案 | 6 | | 议案1 关于公司《2025年股票期权激励计划（草案）》及其摘要的议案 | 6 | | 议案2 关于公司《2025年股票期权激励计划实施考核管理办法》的议案 | 7 | | 议案3 关于提请股东会授权董事会办理公司2025年股票期权激励计划相关事宜的 | | | 议案 8 | | | 议案4 关于聘任独立董事的议案 | 10 | | 议案5 关于变更公司名称及修改《公司章程》的议案 | 11 | | 议案6 关于变更部分募集资金投资项目及金额调整的议案 | 14 | | 议案7 关于补选第三届监事会非职工代表监事的议案 | 18 | 2 四、为保证会场秩序，进入会场后，请关闭手机或调至振动状态。谢绝个人 录音、拍照及录 ...

Core Viewpoint - The National Medical Products Administration (NMPA) has released the "Guidelines for Clinical Resistance Research and Data Submission for Anti-HIV Drugs," establishing a standardized benchmark for HIV drug development in China [2][3]. Group 1: Regulatory Changes - The new guidelines aim to address the urgent issue of HIV drug resistance, which poses significant challenges to treatment efficacy and public health [4]. - The guidelines introduce stricter requirements for drug development, raising the bar for the industry and encouraging companies to develop safer and more effective new drugs [4][5]. Group 2: Company Involvement - Aidi Pharmaceutical, a leading company in the anti-HIV field, actively participated in the formulation of these guidelines, sharing its extensive experience in resistance research [5][6]. - The company has been recognized for its commitment to tackling HIV challenges and has contributed valuable insights during the guideline consultation process [5][6]. Group 3: Research and Development - Aidi Pharmaceutical's existing drugs, such as Ainovelin and Ainomir, have shown excellent clinical performance with low cross-resistance to previous non-nucleoside drugs, providing effective treatment options for patients [7]. - The company is also developing a new integrase inhibitor, ACC017, which has shown promising results in early clinical trials, indicating good safety and efficacy profiles [8]. Group 4: Future Directions - Aidi Pharmaceutical plans to continue increasing its R&D investments and enhancing its innovation capabilities in response to the new guidelines, aiming to develop more high-quality anti-HIV drugs [9]. - The company emphasizes the importance of resistance research in drug development and aims to contribute significantly to China's HIV prevention and treatment efforts [9].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has launched a stock option incentive plan aimed at boosting the sales of its HIV drugs, with specific performance targets set for different groups of employees. The plan is designed to be comprehensive and operationally feasible [4] - The sales of HIV drugs have shown significant growth, with Q1 2025 sales reaching 62 million yuan, a year-on-year increase of 75.64%, marking a historical high for the company [5] - The company is expected to achieve a turnaround in profitability, with projected net profits for 2025-2027 revised to -0.02 billion, 0.44 billion, and 0.88 billion yuan respectively [4] Financial Summary and Valuation Indicators - Revenue is projected to grow from 411.4 million yuan in 2023 to 1,237 million yuan in 2027, with a year-on-year growth rate of 76.4% in 2025 [7] - The gross margin is expected to improve significantly, reaching 72.9% in 2025 and 81.2% by 2027 [7] - The company's price-to-sales (P/S) ratio is projected to decrease from 15.1 in 2023 to 5.0 in 2027, indicating an improving valuation as revenues grow [7]

Meeting Overview - The third meeting of the Supervisory Board of Jiangsu Aidi Pharmaceutical Co., Ltd. was held on June 27, 2025, with all three supervisors present, confirming the legality and validity of the meeting [1]. Resolutions Passed - The Supervisory Board approved the proposal to cancel part of the unvested restricted stock, stating that it complies with relevant laws and regulations, and does not harm shareholders' interests [1][2]. - The Supervisory Board approved the draft of the 2025 Stock Option Incentive Plan, which aligns with legal requirements and is expected to benefit the company's sustainable development [2][3]. - The Supervisory Board approved the implementation assessment management measures for the 2025 Stock Option Incentive Plan, ensuring smooth execution and alignment with the company's governance structure [3][4]. - The Supervisory Board verified the list of initial incentive objects for the 2025 Stock Option Incentive Plan, confirming their qualifications under relevant laws and regulations [4][5]. - The Supervisory Board approved changes to certain fundraising investment projects and amount adjustments, aimed at enhancing operational stability and profitability [5][6]. - The Supervisory Board agreed to nominate Tang Jieqing as a candidate for a non-employee representative supervisor, pending shareholder approval [6][7]. - The Supervisory Board elected current employee representative supervisor Pang Qiuchen as the chairman of the Supervisory Board, effective immediately [7].

Core Viewpoint - Jiangsu Aidi Pharmaceutical Co., Ltd. is adjusting its fundraising investment projects to enhance the efficiency of fund usage and expedite the development of advantageous projects, specifically by reallocating funds from the "Ustectidine New Indication Research Project" to the "Integrase Inhibitor Drug Research and Clinical Study Project" [4][8][14] Fundraising Investment Project Overview - As of June 20, 2025, the raw material drug production research and supporting facilities project has been completed, while other fundraising projects are ongoing [2] - The total amount of committed investment for the projects is 542.8 million yuan, with 396.6 million yuan invested by June 20, 2025 [3] Changes and Amount Adjustments - The company plans to change the name of the project "Ustectidine New Indication Research Project" to "Integrase Inhibitor Drug Research and Clinical Study Project" and adjust the investment amounts accordingly [4][5] - The remaining funds of 84.3699 million yuan from the original project will be fully allocated to the new project to meet its funding needs [6][9] Reasons for Changes - The original project faced delays due to stricter regulatory requirements and the need for further evaluations, prompting the company to reallocate funds to a project with more immediate needs [7][8] - The "Integrase Inhibitor Drug Research and Clinical Study Project" is crucial for the company's pipeline, aiming to develop a new generation of integrase inhibitors for HIV treatment [9][10] Impact of Changes - The adjustments are expected to improve the efficiency of fund usage and support the company's long-term development strategy without adversely affecting normal operations [12][14] - The project aims to enhance the effectiveness and safety of HIV treatments, aligning with national policy goals and expanding the company's product offerings [10][12] Approval Process - The board of directors and the supervisory board have approved the changes, which will be submitted for shareholder approval [13][14]

证券代码：688488 证券简称：艾迪药业 公告编号：2025-032 江苏艾迪药业股份有限公司 关于开立募集资金临时补流专项账户并签署募集资 金临时补流专户存储三方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业股份有限公司（以下简称"艾迪药业"或"公司"）于 2025 年 6 月 27 日召开了第三届董事会第四次会议，审议通过了《关于开立募集资金 临时补流专项账户并签署募集资金临时补流专户存储三方监管协议的议案》，现 将有关情况公告如下： 一、 募集资金基本情况 经中国证券监督管理委员会出具《关于同意江苏艾迪药业股份有限公司首次 公开发行股票注册的批复》 （证监许可〔2020〕1185 号）核准，公司向社会公开 发行人民币普通股 6,000 万股，发行价为每股人民币 13.99 元，募集资金总额为 人民币 839,400,000.00 元，扣除承销费用和保荐费用合计含税金额 61,758,000.00 元，实际募集资金到账 777,642,000.00 元。本次股票发行累计发生发行费用含税 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2025-030 江苏艾迪药业股份有限公司 关于监事会主席辞任暨补选非职工代表监事、监事会 主席的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会主席辞任情况 江苏艾迪药业股份有限公司（以下简称"公司"）监事会于近日收到公司监 事及监事会主席何凤英女士提交的辞任报告，何凤英女士申请辞去公司第三届监 事会非职工代表监事职务，辞任后其将继续在公司任职。 何凤英女士的辞任将导致公司监事会人数低于法定最低要求，根据《中华人 民共和国公司法》《公司章程》相关规定，何凤英女士的辞任将自公司股东会选 举产生新任监事后生效。在股东会选举出新任监事之前，何凤英女士将继续履行 监事职责。 公司于 2025 年 6 月 27 日召开第三届监事会第四次会议，审议通过了《关于 选举公司监事会主席的议案》,全体监事一致同意选举现任职工代表监事庞秋晨 先生（简历详见附件）担任公司第三届监事会主席，任期自本次监事会审议通过 之日起至第三届监事会任期届满之日止。 三、关于提名非职工代表监 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2025-028 江苏艾迪药业股份有限公司 关于变更财务总监的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业股份有限公司（以下简称"公司"）董事会于 2025 年 6 月 27 日召开第三届董事会第四次会议，审议通过了《关于变更财务总监的议案》，现 将相关情况公告如下： 一、财务总监聘任情况 （以下简称" 《公司法》"）、 《江苏艾迪药业股 份有限公司公司章程》 （以下简称"《公司章程》"）等相关规定，经公司董事会提 名委员会资格审查通过，并经审计委员会全体委员同意，公司于 2025 年 6 月 27 日召开第三届董事会第四次会议，审议通过了《关于变更财务总监的议案》。公 司董事会同意聘任董事会秘书刘艳女士兼任公司财务总监职务，任期自本次董事 会审议通过之日起至第三届董事会任期届满之日止。刘艳女士的简历见附件。 刘艳女士具备相应的任职资格，能够胜任财务相关职责的工作，不存在《公 司法》规定的不能担任公司高级管理人员、财务负责人的情形，未受过中国证监 ...

Core Points - The candidate, Hu Wenyuan, has been nominated as an independent director for Jiangsu Aidi Pharmaceutical Co., Ltd. and confirms his qualifications and independence [1][4] - The candidate possesses over five years of relevant experience in biopharmaceutical research, law, economics, accounting, finance, and management [1] - The candidate meets the legal and regulatory requirements for independent directors as outlined by various Chinese laws and regulations [1] - The candidate declares independence and does not fall under any disqualifying conditions related to family ties, shareholding, or business relationships with the company [1][3] - The candidate has no adverse records in the last 36 months, including no administrative or criminal penalties from the China Securities Regulatory Commission [2][3] - The candidate has not been disqualified from serving as an independent director due to attendance issues in previous roles [3] - The candidate has participated in training and holds relevant certification recognized by the stock exchange [6] - The candidate commits to adhering to laws, regulations, and the rules of the Shanghai Stock Exchange while ensuring sufficient time and effort to fulfill his duties [4]